Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1947 5
1948 3
1949 6
1950 13
1951 11
1953 2
1954 1
1955 3
1956 4
1957 3
1959 2
1960 1
1961 4
1962 1
1965 1
1966 1
1967 1
1968 3
1969 3
1970 2
1971 3
1972 8
1973 6
1974 3
1975 6
1976 10
1977 4
1978 7
1979 9
1980 16
1981 8
1982 5
1983 3
1984 14
1985 6
1986 12
1987 8
1988 6
1989 9
1990 14
1991 17
1992 14
1993 13
1994 11
1995 11
1996 8
1997 21
1998 13
1999 36
2000 26
2001 36
2002 16
2003 28
2004 28
2005 32
2006 29
2007 28
2008 23
2009 28
2010 41
2011 42
2012 55
2013 48
2014 51
2015 43
2016 61
2017 70
2018 56
2019 69
2020 80
2021 75
2022 96
2023 85
2024 90
2025 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,507 results

Results by year

Filters applied: . Clear all
Page 1
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Among authors: andre m. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.
Reply.
de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Pérard L, Cornut PL, Schneider C, Rivière S, Ollé P, Pugnet G, Cathébras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Vicente S, Bin S, Broussolle C, Decullier E, Sève P. de Parisot A, et al. Among authors: andre m. Am J Ophthalmol. 2017 Jul;179:208-209. doi: 10.1016/j.ajo.2017.04.023. Epub 2017 May 17. Am J Ophthalmol. 2017. PMID: 28528083 No abstract available.
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Brody JD, Jørgensen J, Belada D, Costello R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, André M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Brody JD, et al. Among authors: andre m. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830. Blood. 2025. PMID: 39792928 Free PMC article. Clinical Trial.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Bachy E, et al. Among authors: andre m. J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29. J Clin Oncol. 2022. PMID: 34843406 Clinical Trial.
[Craniofacial fibrous dysplasia].
Couturier A, Aumaître O, Mom T, Gilain L, André M. Couturier A, et al. Among authors: andre m. Rev Med Interne. 2016 Dec;37(12):834-839. doi: 10.1016/j.revmed.2016.02.008. Epub 2016 Mar 23. Rev Med Interne. 2016. PMID: 27017329 French.
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. Dupuis J, et al. Among authors: andre m. Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9. Lancet Haematol. 2024. PMID: 38796193 Clinical Trial.
Editorial: New insights in the microbe-vector interaction.
Qi Y, Zhang J, André MR, Qin T. Qi Y, et al. Among authors: andre mr. Front Microbiol. 2024 Jan 16;15:1364989. doi: 10.3389/fmicb.2024.1364989. eCollection 2024. Front Microbiol. 2024. PMID: 38292250 Free PMC article. No abstract available.
1,507 results